Citron's Left Keeps Changing His Position on Valeant (VRX) - Ackman
On CNBC, Bill Ackman commented on Citron Research's Andrew Left new short on Valeant Pharma ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)